HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer

• Status: Terminated
• Trial end date: 2020-03-20
• Target enrollment: 0
• Participant gender: All

Summary

The prognosis of patients with unresectable peritoneal metastases from gastric cancer is poor. These patients may obtain survival benefit from radical gastrectomy and cytoreductive surgery (CRS). The response rates of previous conversion therapy are low. Hyperthermic intraperitoneal chemoperfusion (HIPEC) and systemic chemotherapy are effective methods of reducing peritoneal cancer index (PCI) levels. Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2), shows significant antitumor activity in the patients with gastric cancer. The purpose of this study is to investigate the efficacy and safety of HIPEC and systemic chemotherapy combined with Apatinib in the conversion therapy of peritoneal metastases from gastric cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wuhan University
• Treatments: Apatinib; Oxaliplatin

Criteria

Inclusion Criteria:

• Histological proved diagnosis of gastric cancer.

• Unresectable peritoneal metastases and primary tumor proved at surgery.

• No evidence of distant metastases.

• Have not received radiotherapy, chemotherapy or immunotherapy.

• ECOG score: 0~2.

• Written informed consent is obtained prior to commencement of trial treatment.

Exclusion Criteria:

• Existence of distant metastasis outside the abdomen.

• Any previous radiotherapy, chemotherapy or immunotherapy.

• Active systemic infections.

• Inadequate cardiac function, renal function, liver function or bone marrow function at the beginning of the trial.

• Female patients who are pregnant or breast feeding